GLG News by Corrective Refractive Laser Surgeons (US)

LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA. This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis. In a field where there are few approved treatment modalities, this could be very big...

This brief article describes the comments of the Advanced Medical Optics (AMO) President and CEO which deflect the blame of the recent contact lens infection on the consumer on poor contact lens hygiene.  Although the comments of the AMO brass may be indeed true, there is not a single entity to...

It seems most likely that the reason that the major ophthalmic houses did not want the Crystalens-Eyeonics company is that the technology has substantial problems.  Unlike the multifocal lenses, in order to give the best possible distance vision, near vision is not...

Biodem (ASX:BDM) is conducting a a Phase I/II trail involving a 10 day course of subcutaneous injection of a peptide in the treatment of diabetic macular edema.  The results of this trial which is being conducted abroad in Russia will be available in November 2007. Although promising...

LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA.  This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis.  In a field where there are few approved treatment modalities, this could...

Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena.  The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...

Tears of the retinal pigment epithelium (RPE) may develop during the course of anti-VEGF therapy for age-related macular degeneration (AMD) related pigment epithelial detachment (PED), according to a study published in the June issue of Retina.  A total of 33 cases of RPE tear after treatment with...

This glaucoma drug efficacy crossover study shows that bimatoprost (Lumigan) from AGN lowers intraocular pressure better than latanoprost (Xalatan) from PFE in a special subset of glaucoma patients (exfoliative glaucoma).  The difference is only 1 mm Hg which may be statistically significant will...

Bayer and Regeneron are moving forward with their Phase 3 Trial called the VIEW involving VEGF Trap for the treatment for choroidal neovascularization in Age Related Macular Degeneration.  The implications are large for a billion dollar market that is currently dominated by Lucentis (DNA).

Bad news merger of AMO and B&L..